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Summary
Background Luteinising-hormone-releasing-hormone agonists (LHRHa) to treat prostate cancer are associated with 
long-term toxic eﬀ ects, including osteoporosis. Use of parenteral oestrogen could avoid the long-term complications 
associated with LHRHa and the thromboembolic complications associated with oral oestrogen.
Methods In this multicentre, open-label, randomised, phase 2 trial, we enrolled men with locally advanced or 
metastatic prostate cancer scheduled to start indeﬁ nite hormone therapy. Randomisation was by minimisation, in a 
2:1 ratio, to four self-administered oestrogen patches (100 μg per 24 h) changed twice weekly or LHRHa given 
according to local practice. After castrate testosterone concentrations were reached (1·7 nmol/L or lower) men 
received three oestrogen patches changed twice weekly. The primary outcome, cardiovascular morbidity and mortality, 
was analysed by modiﬁ ed intention to treat and by therapy at the time of the event to account for treatment crossover 
in cases of disease progression. This study is registered with ClinicalTrials.gov, number NCT00303784.
Findings 85 patients were randomly assigned to receive LHRHa and 169 to receive oestrogen patches. All 
85 patients started LHRHa, and 168 started oestrogen patches. At 3 months, 70 (93%) of 75 receiving LHRHa 
and 111 (92%) of 121 receiving oestrogen had achieved castrate testosterone concentrations. After a median 
follow-up of 19 months (IQR 12–31), 24 cardiovascular events were reported, six events in six (7·1%) men in the 
LHRHa group (95% CI 2·7–14·9) and 18 events in 17 (10·1%) men in the oestrogen-patch group (6·0–15·6). 
Nine (50%) of 18 events in the oestrogen group occurred after crossover to LHRHa. Mean 12-month changes in 
fasting glucose concentrations were 0·33 mmol/L (5·5%) in the LHRHa group and –0·16 mmol/L (–2·4%) in 
the oestrogen-patch group (p=0·004), and for fasting cholesterol were 0·20 mmol/L (4·1%) and –0·23 mmol/L 
(–3·3%), respectively (p<0·0001). Other adverse events reported by 6 months included gynaecomastia (15 [19%] 
of 78 patients in the LHRHa group vs 104 [75%] of 138 in the oestrogen-patch group), hot ﬂ ushes (44 [56%] vs 
35 [25%]), and dermatological problems (10 [13%] vs 58 [42%]).
Interpretation Parenteral oestrogen could be a potential alternative to LHRHa in management of prostate cancer if 
eﬃ  cacy is conﬁ rmed. On the basis of our ﬁ ndings, enrolment in the PATCH trial has been extended, with a primary 
outcome of progression-free survival.
Funding Cancer Research UK, MRC Clinical Trials Unit.
Introduction
Around 900 000 men worldwide are diagnosed as having 
prostate cancer every year,1 and more than 40% receive 
androgen-deprivation therapy (ADT) within 6 months of 
diagnosis.2 ADT is the standard treatment for metastatic 
disease, but is also used at earlier stages as adjuvant and 
neoadjuvant therapy in men who require radical 
treatment for localised disease and for those with rising 
concentrations of prostate-speciﬁ c antigen (PSA) who 
are at high risk of distant metastases.3
The immediate eﬀ ects of castration are loss of male 
secondary sexual characteristics, impotence, muscle 
weakness, and changes in body composition.4
ADT is most frequently achieved with luteinising-
hormone-releasing-hormone agonists (LHRHa), but 
these drugs are associated with long-term toxic eﬀ ects, 
including de creased bone-mineral density,5,6 osteoporotic 
fractures,7–10 adverse metabolic changes,11 and diabetes.10,12,13 
Whether this treatment leads to cardio vascular 
complications is unclear because evidence is inconsistent. 
A joint advisory statement from the American Heart 
Association, American Cancer Society, and American 
Urological Association, while noting the inconsistencies 
in the data, advocates careful management of cardiac 
disease in patients with prostate cancer treated with 
ADT.14 Additionally, the US Food and Drug Administration 
requires LHRHa drug labels to warn of an increased risk 
of diabetes and cardiovascular disease.
Continuous exposure to LHRHa leads to down regulation 
of pituitary receptors and hormones, and, subsequently, 
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castrate concentrations of testosterone. Oestrogens in men 
are derived from the aromatisation of androgens and, 
therefore, LHRHa also reduce oestrogen concentrations. 
Thus, men can develop toxic eﬀ ects related to low 
concentrations of these two sex hormones.4 The use of 
oestrogen is an alternative approach to ADT in men. It 
decreases testosterone concentrations in serum by 
inhibition of the hypothalamic-pituitary axis but, unlike 
LHRHa, is not associated with toxic eﬀ ects related to 
oestrogen depletion. Oral oestrogen (eg, diethylstilbestrol) 
was used for ADT before the development of LHRHa, but 
is no longer used routinely because it is associated with an 
increased risk of thrombotic complications15 attributed to 
the eﬀ ects of ﬁ rst-pass hepatic metabolism on coagulation 
proteins and lipids.16 Administration of oestrogen 
parenterally (intravenously, intramuscularly, or 
transcutaneously) avoids ﬁ rst-pass hepatic metabolism 
and, therefore, is not expected to be associated with the 
same thrombotic complications as oral oestrogen.16,17 
Parenteral oestrogen could, therefore, be a potential 
therapeutic alternative to LHRHa. We did the Prostate 
Adenocar cinoma: TransCutaneous Hormones versus 
luteinising hormone-releasing hormone agonists 
(PATCH) ran domised, phase 2 trial to assess the safety and 
activity of transdermal oestrogen patches in the treatment 
of prostate cancer.
Methods
Patients
Eligible men had locally advanced or metastatic prostate 
cancer (including those previously treated with radical 
intent with rising concentrations of PSA) and scheduled 
to start continuous indeﬁ nite hormone therapy at multiple 
hospitals in the UK. They were also required to have 
testosterone concentrations of 6·0 nmol/L or higher and a 
WHO performance status score of 0–2. Administration of 
radical radiotherapy to the prostate was not initially 
permitted, but was later allowed to reﬂ ect changes in 
practice. All patients underwent electrocardiography and 
chest radiography. Echocardi ography was added to 
Figure 1: Trial proﬁ le
Randomisation was 2:1 (oestrogen patches:LHRHa). LHRHa=luteinising-hormone-releasing-hormone agonists. OP=oestrogen patches. *One patient did not start 
treatment, withdrew soon after randomisation, and did not attend any trial visits. †Men with oestradiol concentraions of 250 pmol/L or lower were assumed not to 
be using OP and were excluded. ‡Includes a small number of individuals (maximum 3) who had been assumed not to be receiving treatment at an earlier time (eg, 
owing to low oestradiol concentrations, reported diﬃ  culty in using OP, or missed appointments). 
32 started regimen 1* 136 started regimen 2
169 assigned OP (33 regimen 1, 136 regimen 2)
 3 excluded
    1 died
    1 low oestradiol concentration†
    1 stopped treatment
14 excluded
        1 died
      11 low oestradiol concentration†
        2 stopped treatment
29 continued OP regimen 1 without 
      additional therapy
122 continued OP regimen 2 without 
         additional therapy
3 excluded 
    1 low oestradiol concentration†
    1 stopped treatment
    1 additional therapy 
12 excluded 
      1 died
      9 low oestradiol concentration†
      2 additional therapy 
26 continued OP regimen 1 without 
       additional therapy
112 continued OP regimen 2 without 
         additional therapy‡
6 excluded
    5 low oestradiol concentration†
    1 stopped treatment
19 excluded
      10 low oestradiol concentration†
        5 stopped treatment
4 died
20 continued OP regimen 1 without 
       additional therapy
 93 continued OP regimen 2 without 
        additional therapy‡
85 started treatment
254 patients randomised
6 excluded
    3 died
    1 additional therapy
    1 stopped treatment
    1 missed LHRHa injection
79 continued LHRHa without 
       additional therapy
1 excluded for additional therapy
79 continued LHRHa without 
      additional therapy‡
7 excluded
    2 died
    5 additional therapy
72 continued LHRHa without 
      additional therapy
85 assigned LHRHa
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baseline investigations if a patient had a history of 
ischaemic heart disease. Other baseline investigations 
were physical examinations (including blood pressure), 
bone scans, CT or MRI at the discretion of the physician, 
and blood tests, including measurement of PSA 
concentration. Cardiovascular exclusion criteria were 
stroke or transient ischaemic attack within the previous 
2 years; radiologically conﬁ rmed deep-vein thrombosis or 
pul monary embolism at any time; myocardial infarction 
in the 6 months before the study or more than 6 months 
previously with evidence of q-wave infarction on 
electrocardiography at screening; angina (New York Heart 
Association grade III or higher) in the previous year; 
symptoms of heart failure (New York Heart Association 
grade III or higher); pulmonary oedema evident on chest 
radiography at screening; left-ventricular ejection fraction 
of 40% or lower in patients with a history of ischaemic 
heart disease or heart failure; and systolic blood pressure 
of 160 mmHg or higher and, diastolic blood pressure of 
100 mmHg or higher, or both, in men. Other exclusion 
criteria were previous systemic therapy or previous or 
current malignant disease or cardiovascular disease 
thought likely to compromise the patient’s ability to 
tolerate therapy or aﬀ ect assessment.
The protocol was approved by national regulatory and 
ethics committees and participating hospitals obtained 
the appropriate local approvals. Participants provided 
written informed consent.
Randomisation
Men were allocated in a 2:1 ratio to receive oestrogen 
patches or LHRHa. Randomisation was done centrally 
at the trials unit, according to a computer-based 
minimisation algorithm with a random element (80%) 
balanced for the following factors: disease stage, age, 
smoking status, personal or family history of heart 
disease, and which LHRHa agent was to be used. Staﬀ  at 
the study centres contacted the trials unit by telephone to 
obtain allocation details. The trial was open-label, but 
primary outcome events were reviewed by an 
independent endpoint review committee that was 
unaware of treatment allocation.
Procedures
Initially, patients in the oestrogen-patch group received 
three patches (100 μg per 24 h) to be self-administered and 
changed twice weekly for 4 weeks. The number of patches 
was reduced to two twice weekly if castrate testosterone 
concentrations in serum of 1·7 nmol/L or lower were 
achieved (regimen one). This biweekly regimen was based 
on previous data18 and was intended to be practical and to 
achieve castrate testosterone concentrations quickly and 
maintain them. The ﬁ rst review by the independent data 
monitoring committee showed that oestradiol 
concentrations were lower and testosterone responses 
were less frequent than anticipated. The regimen was 
changed, therefore, to four patches to be changed twice 
weekly for 4 weeks, followed by use of three patches twice 
weekly when the target castrate testos terone concentration 
in serum was reached (regimen two).19 Patients with 
testosterone concentrations higher than castrate levels at 
4 weeks remained on the induction regimen and had 
testosterone checked every 2 weeks. LHRHa was 
prescribed according to local practice and could be 
accompanied by a short course of antiandrogens to treat 
 LHRHa (n=85) OP (n=169)
Age at randomisation (years)
Median (IQR) 75 (69–80) 73 (69–78)
Range 56–92 49–90
PSA concentration (ng/mL)
Median (IQR) 36 (19–106) 55 (21–153)
<50 53 (62%) 78 (46%)
50–500 28 (33%) 75 (45%)
>500 4 (5%) 15 (9%)
Unknown 0 1
Gleason sum score
4–6 10 (13%) 16 (10%)
7 33 (42%) 60 (38%)
8–10 35 (45%) 83 (52%)
Unknown 7 10
T category
T0/X 7 (8%) 11 (7%)
T1/2 5 (6%) 10 (6%)
T3 59 (69%) 129 (76%)
T4 14 (16%) 19 (11%)
N category
N0 28 (33%) 43 (25%)
N+ 17 (20%) 36 (21%)
NX 40 (47%) 90 (53%)
M category
M0 53 (62%) 110 (65%)
M1 32 (38%) 59 (35%)
Regular long-term aspirin use 24 (28%) 46 (27%)
Smoking history
Never 38 (45%) 74 (44%)
Previous 37 (44%) 72 (43%)
Current 10 (12%) 23 (14%)
WHO performance status
Normal activity 56 (66%) 118 (70%)
Avoid strenuous activity 22 (26%) 40 (24%)
Up and about >50% 7 (8%) 11 (7%)
Mean (SD, n) fasting cholesterol concentration (mmol/L) 5·0 (1·2, n=80) 4·7 (1·1, n=162)
Mean (SD, n) fasting glucose (mmol/L) 5·7 (1·0, n=81) 5·7 (1·2, n=161)
Mean (SD, n) weight (kg) 80·1 (12·9, n=77) 82·0 (13·1, n=153)
Mean (SD, n) blood pressure (mm Hg)
Systolic 144 (14·9, n=80) 140 (15·3, n=165)
Diastolic 79 (10·2, n=80) 79 (9·2, n=165)
Data are n (%) unless otherwise indicated. LHRHa=luteinising-hormone-releasing hormone agonists. OP=oestrogen 
patches. 
Table 1: Baseline characteristics of the study population by allocated treatment
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tumour ﬂ are. Testosterone and PSA concen trations were 
checked regularly in all participants. In cases of disease 
progression, patients could be given second-line therapy 
at the discretion of the treating clinician, including 
changing to the non-assigned study treatment.
The primary outcome measure was cardiovascular 
morbidity and mortality, according to the following 
prespeciﬁ ed deﬁ nitions: new symptoms or clinical signs 
of decompensated cardiac failure, supported by chest 
radiography, echocardiography, or a rise in concentration 
of brain natriuretic peptide; acute coronary syndrome 
(including unstable angina, non-ST-segment-elevation 
myocardial infarction, and myocardial infarction) pre-
senting as new-onset cardiac chest pain, collapse, or 
shortness of breath, and conﬁ rmed as ischaemic in 
origin by electrocardiography, troponin rise, coronary 
angiography, or a combination of these tests; new 
neurological symptoms and signs of a cerebrovascular 
accident, conﬁ rmed by brain CT or MRI or by clinical 
diagnosis and carotid duplex scanning for transient 
ischaemic attacks, with evidence of pre-existing or new, 
persistent or paroxysmal atrial ﬁ brillation; new clinical 
symptoms supported by radiological evidence of other 
arterial embolic events; venous thromboembolism 
conﬁ rmed by ultra sonography, venography, or both, or 
pulmonary em bolism conﬁ rmed by CT pulmonary 
angiogram, ventilation-perfusion scans, or angi ography; 
and other relevant events (deaths attributed to one of 
these cardiovascular causes without supporting docu-
mentation, or events that did not meet the exact 
deﬁ nitions but were judged appropriate for inclusion by 
the independent reviewers).
Cardiac events were reported by investigators at 3 and 
6 months and 6-monthly thereafter on a speciﬁ cally 
designed form or identiﬁ ed from reports of serious 
adverse events and routinely collected data on toxic 
eﬀ ects. Two independent reviewers unaware of original 
treatment allocation or current treatment being received 
reviewed original documentation and decided which 
events met the primary outcome deﬁ nitions and whether 
or not they were related to hormone therapy. Discrep-
ancies in classiﬁ cation were resolved by discussion, 
assessment of further clinical information, or both.
Secondary outcomes were hormone responses and 
other adverse events, including changes in 
cardiovascular risk factors (concentrations of fasting 
glucose, fasting total cholesterol, and HDL cholesterol, 
weight, and blood pressure) and other toxic eﬀ ects. 
Severity of events was assigned according to the 
Common Terminology Criteria for Adverse Events 
(version 3.0). Laboratory assessments of hormones and 
metabolic factors were done in the participating 
hospitals without central validation.
Statistical analysis
We estimated that around 8% of men receiving LHRHa 
would have a cardiovascular event, on the basis of 
previous data.20 As a phase 2 trial, the analysis was not 
powered to compare arms. A sample size of 200 patients, 
of whom 133 would be randomised to receive oestrogen 
patches, was calculated to be large enough to estimate 
the cardiovascular event rate in the oestrogen-patch 
group with reasonable precision. The LHRHa group 
acted as a benchmark in view of the uncertainty about 
the underlying cardiovascular risk in the cohort. The 
2:1 randomisation ratio was designed to maximise 
experience with oestrogen patches. After regimen two 
was introduced in the oestrogen-patch group, the 
required sample size was increased to 250 patients 
overall (133 to regimen two). If strong evidence of a 15% 
or higher cardiovascular-event rate in the oestrogen-
patch arm was seen (based on the lower limit of a 
95% CI), an early review by the independent data 
monitoring committee would be triggered and trial 
closure could be considered. The numbers of events 
required to trigger a review were ten or more in the ﬁ rst 
33 patients assigned oestrogen patches, 17 in 67 patients, 
23 in 100 patients, and 29 in 133 patients.
The primary cardiovascular analysis was based on 
modiﬁ ed intention-to-treat principles: patients were 
assessed in the oestrogen-patch group if they had been 
treated with patches at any point, and assessed in the 
LHRHa group if they had received LHRHa but not 
patches at any point; patients who received no treatment 
at all were excluded. This approach was expected to be 
conservative because it maximised the number of events 
attributed to oestrogen patches. The proportion of 
Intention-to-treat analysis* Treatment at time 
of event†
LHRHa (n=84) OP (n=169) LHRHa OP
Cardiovascular events
Number of events (fatal events) 6 (1) 18 (5) 15 (4) 9 (2)
Number of patients 6 (7%) 17 (10%) 15‡  9‡
Type of event (fatal events)
Heart failure 0 3 (1) 3 (1) 0
Acute coronary syndrome 2 (1) 6 (1) 5 (2) 3 (0)
Thromboembolic stroke 1 (0) 4 (1) 2 (0) 3 (1)
Other arterial embolic events 0 1 (1) 0 1 (1)
Venous thromboembolism 3 (0) 4 (1) 5 (1) 2 (0)
Rate of events per 100 patients 7·1 10·7 NA NA
Proportion (exact binomial 95% CI) 
of patients with events (%)
7·1% (2·7–14·9) 10·1% (6·0–15·6) NA NA
Total reviewed events that did not 
satisfy outcome deﬁ nitions
10 21 14 17
LHRHa=luteinising-hormone-releasing-hormone agonists. OP=oestrogen patches. *In the modiﬁ ed intention-to-treat 
population, patients were included in the OP group if they had been treated with OP at any point; patients were 
included in the LHRHa group if they had been treated with an LHRHa and had not received OP at any point. One patient 
assigned to LHRHa who received some OP treatment was included in the OP group, and one assigned to OP who 
received no treatment was excluded. †Events within 30 days of changing treatments were assigned to the original 
treatment. ‡One patient had two events, one while using OP and one while taking LHRHa, and is included in both 
columns. 
Table 2: Cardiovascular events
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patients who experienced an event is reported with exact 
binomial 95% CIs. As crossover was allowed in the case 
of disease progression, we did a planned sensitivity 
analysis in which we included numbers of events 
according to treatment being taken at the time of (or 
within 30 days before) the events. Analysis of the 
primary outcome was planned for 3 months after the 
last randomisation to enable a prompt decision 
regarding continuation of the study, whereas assessment 
of the secondary outcomes were done 15 months after 
the last randomisation to enable assessment of changes 
over time. Secondary outcomes were assessed in men 
who were still receiving their assigned study treatment 
with no additional prostate-cancer therapy at the time of 
interest. Men with oestradiol concentrations of 
250 pmol/L or lower, or who were reported to have 
stopped using patches (where oestradiol data were not 
available) were not assessed. Castration rates (proportion 
of men with testosterone concentrations of 1·7 nmol/L 
or lower) at 3 months and 6 months are reported. Post-
hoc analyses included the proportions of patients who 
achieved lower testosterone thresholds (1·1 mmol/L 
and 0·7 nmol/L) and diﬀ erences between LHRHas. 
Cardiovascular risk factors are re ported as mean 
(95% CI) at 6 and 12 months, as well as mean (%) 
changes from baseline. Treatment eﬀ ects were 
investigated with ANCOVA models adjusted for 
baseline values. Checks of model assumptions and ﬁ t 
included assessment of residual plots and tests. We did 
no formal treatment comparisons of toxic eﬀ ects. All 
analyses were done with Stata statistical software 
(version 12).
Number of 
patients
Mean (95% CI) at 
baseline
Mean (95% CI) at 
time of assessment
Mean change 
(range)
Mean 
change (%)
Treatment 
eﬀ ect p value*
6 months
Fasting glucose (mmol/L)
LHRHa 55 5·76 (5·48–6·04) 5·82 (5·53–6·12) 0·06 (–2·5 to 2·4) 2·0% 0·035
OP 107 5·59 (5·43–5·74) 5·44 (5·27–5·61) –0·15 (–2·0 to 3·0) –2·1%
Fasting cholesterol (mmol/L)
LHRHa 59 4·99 (4·73–5·26) 5·35 (5·00–5·69) 0·35 (–2·4 to 3·1) 7·6% <0·0001
OP 119 4·81 (4·62–4·99) 4·68 (4·51–4·85) –0·13 (–2·9 to 2·1) –1·2%
Fasting HDL (mmol/L)
LHRHa 58 1·30 (1·21–1·38) 1·41 (1·30–1·53) 0·12 (–0·5 to 1·4) 10·1% 0·35
OP 108 1·29 (1·23–1·36) 1·45 (1·37–1·53) 0·16 (–0·6 to 1·1) 13·6%
Weight (kg)
LHRHa 56 80·95 (77·35–84·55) 83·03 (79·30–86·76) 2·09 (–5·2 to 20·8) 2·7% 0·71
OP 107 82·04 (79·56–84·53) 83·91 (81·29–86·53) 1·87 (–9·0 to 11·0) 2·3%
Systolic blood pressure† (mm Hg)
LHRHa 60 144·0 (115·2–165·7) 142·0 (110·1–179·8) 0 (–39·0 to 50·0) 0 0·21
OP 116 140·0 (113·0–160·6) 137·0 (110·0–172·2) 1·0 (–42·0 to 55·0) –0·8%
Diastolic blood pressure (mm Hg)
LHRHa 60 79·2 (76·7–81·7) 81·0 (78·0–84·0) 1·80 (–27·0 to 30·0) 2·9% 0·011
OP 116 78·8 (77·2–80·3) 76·6 (74·5–78·7) –2·18 (–31·0 to 27·0) –2·4%
12 months
Fasting glucose (mmol/L)
LHRHa 54 5·70 (5·43–5·98) 6·03 (5·54–6·52) 0·33 (–2·0 to 6·9) 5·5% 0·004
OP 95 5·50 (5·35–5·65) 5·34 (5·16–5·51) –0·16 (–1·9 to 2·4) –2·4%
Fasting cholesterol (mmol/L)
LHRHa 55 5·11 (4·83–5·39) 5·31 (4·94–5·68) 0·20 (–2·9 to 1·9) 4·1% <0·0001
OP 101 4·79 (4·59–5·00) 4·56 (4·39–4·73) –0·23 (–3·1 to 1·9) –3·3%
Fasting HDL (mmol/L)
LHRHa 52 1·29 (1·21–1·37) 1·36 (1·24–1·47) 0·07 (–0·9 to 0·8) 5·3% 0·33
OP 91 1·27 (1·20–1·34) 1·38 (1·30–1·46) 0·11 (–0·3 to 1·0) 9·5%
Weight (kg)
LHRHa 47 81·77 (77·92–85·61) 83·86 (79·61–88·11) 2·09 (–14·0 to 14·7) 2·5% 0·70
OP 83 80·93 (78·06–83·81) 83·24 (80·10–86·38) 2·31 (–8·0 to 10·0) 2·7%
LHRHa=luteinising-hormone-releasing-hormone agonists. OP=oestrogen patches. *Tests for treatment eﬀ ect are based on ANCOVA models with adjustment for baseline 
values. †Owing to distribution, data are presented as median (5th and 95th percentiles) at baseline and 6 months, median change (range), and median percentage change. 
Log-transformed values were used for the ANCOVA model.
Table 3: Cardiovascular risk factors in men who remained on randomised treatment without additional therapy
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In this study, we report data from the preplanned 
analysis of cardiovascular outcomes in the ﬁ rst 
254 patients. On the basis of recommendations from the 
independent data monitoring committee, the study was 
extended to assess progression-free survival in 660 men 
(including this initial cohort). To maintain the integrity 
of the ongoing study, data on disease status during 
follow-up are not presented.
The trial is registered with ISRCTN Register and 
ClinicalTrials.gov, numbers ISRCTN70406718 and 
NCT00303784.
Role of the funding source
The sponsor of the study had no role in the study design, 
data collection, data analysis, data interpretation, or 
writing of the report. REL, FHC, SCF, and RCJ had 
access to the raw data, and processed data released by 
the independent data monitoring committee were 
available to all authors. REL, FHC, and PDA were jointly 
responsible for the decision to submit for publication.
Results
Between April 7, 2006, and April 28, 2010, 254 patients 
from 27 UK centres were enrolled, 169 into the oestrogen-
patch group (33 regimen one, 136 regimen two) and 85 
into the LHRHa group. With the exception of one patient 
assigned to oestrogen patches, all men started their 
assigned treatment (ﬁ gure 1). Characteristics at 
randomisation were much the same between groups 
(table 1). Median age was 74 years (IQR 69–79), 91 (36%) 
patients had metastatic disease, 236 (93%) had WHO 
performance status scores of 0 or 1, 142 (56%) were 
current or previous smokers, and 70 (28%) were long-
term regular aspirin users. Five (2%) men had undergone 
radical radiotherapy (three in the oestrogen-patches 
group and two in the LHRHa group).
At 3 months, among men who were still receiving 
their allocated treatment without additional therapy, 
70 (93%) of 75 with data available in the LHRHa 
group and 111 (92%) of 121 receiving oestrogen patches 
under regimen two had testosterone concentrations of 
1·7 nmol/L or less. By contrast, 20 (69%) of 29 receiving 
oestrogen patches under regimen one had castrate 
concentrations of testosterone. The castration rate in the 
LHRHa group did not diﬀ er by agonist used (28 [93%] of 
30 for leuprorelin, 41 [93%] of 44 for goserelin, and one 
[100%] of one for triptorelin). Testosterone concentrations 
of 1·1 mmol/L or lower were seen in 53 (71%) of 75, 
94 (78%) of 121, and 14 (48%) of 29 men who received 
LHRHa, oestrogen-patch regimen two, and oestrogen-
patch regimen one, respectively, and concentrations of 
0·7 nmol/L or lower were seen in 44 (59%) of 75, 
75 (62%) of 121, and nine (31%) of 29.
At 6 months, 68 (88%) of 77 patients with available 
data had testosterone concentrations of 1·7 nmol/L or 
lower in the LHRHa group, compared with 106 (95%) of 
112 in the oestrogen-patch group receiving regimen two 
and 20 (77%) of 26 of those receiving regimen one. 
Testosterone breakthrough was seen at 6 months in six 
(9%) of 68 in the LHRHa group and four (4%) of 104 in 
the oestrogen-patch group (regimen two) who had had 
castrate concentrations at 3 months. Oestradiol 
concentrations higher than 250 pmol/L indicated that 
adherence to treatment with oestrogen patches was 
generally good, and at 3 months most (117 [96%] of 122) 
men randomised to receive oestrogen-patch regimen 
two had changed to the maintenance regimen of three 
patches; two (2%) were using two patches and three 
(2%) were using four patches.
Median follow-up for cardiovascular events was 
19 months (IQR 12–31, minimum 3 months). 55 potential 
events were identiﬁ ed among patients in the modiﬁ ed 
intention-to-treat cohort, of which 24 met the outcome 
deﬁ nitions (table 2). The number of patients with an 
event in the LHRHa group was six (7·1%) of 84 (95% CI 
2·7–14·9, six events) and in the oestrogen-patches group 
was 17 (10·1%) of 169 (6·0–15·6, 18 events). The number 
of events in the oestrogen-patch group remained lower 
than the predeﬁ ned criteria for early review by the 
independent data monitoring committee throughout the 
trial. The rate of cardiovascular events was 2·9% higher 
in the oestrogen-patch group than in the LHRHa group 
(95% CI –4·2 to 10·1). The wide 95% CI suggests no 
signiﬁ cant diﬀ erence between groups, although the trial 
was not designed to test this comparison.
Figure 2: Changes in fasting glucose (A) and total cholesterol (B) concentrations in patients still receiving 
treatment at 6 and 12 months
Patients were not receiving additional therapy. Boxes indicate median and IQR, whiskers indicate 1·5×IQR, and dots 
indicate outlying values. LHRHa=luteinising-hormone-releasing-hormone agonists. OP=oestrogen patches.
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LHRHa (n=78*) OP regimen 
one (n=26)
OP regimen 
two (n=112)
Endocrine/sexual
Gynaecomastia
0 63 (81%) 8 (31%) 26 (23%)
1–2 15 (19%) 15 (57%) 76 (68%)
3 0 3 (12%) 10 (9%)
Erectile dysfunction†
0 36 (47%) 9 (35%) 49 (45%)
1–2 33 (43%) 15 (58%) 54 (49%)
3 8 (10%) 2 (8%) 7 (6%)
Decreased libido‡
0 39 (51%) 8 (31%) 52 (47%)
1–2 37 (49%) 18 (69%) 55 (50%)
3 0 0 3 (3%)
Hot ﬂ ushes
0 34 (44%) 18 (69%) 85 (76%)
1–2 44 (56%) 8 (31%) 27 (24%)
Dermatological§
Pruritis
0 74 (95%) 21 (81%) 82 (73%)
1–2 4 (5%) 5 (19%) 30 (27%)
Erythema
0 77 (99%) 21 (81%) 86 (77%)
1–2 1 (1%) 5 (19%) 26 (23%)
Eczema
0 76 (97%) 24 (92%) 105 (94%)
1–2 2 (3%) 2 (8%) 7 (6%)
Urticaria
0 77 (99%) 24 (92%) 102 (91%)
1–2 1 (1%) 2 (8%) 10 (9%)
Change in skin pigmentation
0 78 (100%) 24 (92%) 111 (99%)
1–2 0 2 (8%) 1 (1%)
Hair changes
0 75 (96%) 26 (100%) 110 (98%)
1–2 3 (4%) 0 2 (2%)
Neurological
Anxiety
0 64 (82%) 24 (92%) 100 (89%)
1–2 14 (18%) 2 (8%) 12 (11%)
Depression
0 64 (82%) 20 (77%) 101 (90%)
1–2 13 (17%) 6 (23%) 11 (10%)
3 1 (1%) 0 0
Inability to 
concentrate
0 62 (79%) 15 (58%) 104 (93%)
1–2 16 (21%) 11 (42%) 8 (7%)
Increased irritability
0 62 (79%) 23 (88%) 101 (90%)
1–2 16 (21%) 3 (12%) 11 (10%)
Headache
(Continues in next column)
LHRHa (n=78*) OP regimen 
one (n=26)
OP regimen 
two (n=112)
(Continued from previous column)
0 72 (92%) 25 (96%) 108 (96%)
1–2 6 (8%) 1 (4%) 4 (4%)
Paraesthesia
0 77 (99%) 25 (96%) 111 (99%)
1–2 1 (1%) 1 (4%) 1 (1%)
Dizziness
0 68 (87%) 23 (88%) 107 (96%)
1–2 9 (12%) 3 (12%) 5 (4%)
3 1 (1%) 0 0
Gastrointestinal
Nausea
0 74 (95%) 24 (92%) 109 (97%)
1–2 4 (5%) 2 (8%) 3 (3%)
Vomiting
0 76 (97%) 26 (100%) 111 (99%)
1–2 2 (3%) 0 1 (1%)
Abdominal pain
0 71 (91%) 24 (92%) 112 (100%)
1–2 7 (9%) 2 (8%) 0
Dyspepia
0 73 (94%) 25 (96%) 109 (97%)
1–2 5 (6%) 1 (4%) 3 (3%)
Constitutional and other symptoms
Fatigue
0 46 (59%) 16 (62%) 85 (76%)
1–2 32 (41%) 10 (38%) 26 (23%)
3 0 0 1 (1%)
Insomnia
0 66 (85%) 20 (77%) 100 (89%)
1–2 12 (15%) 6 (23%) 12 (11%)
3 0 0 0
Appetite increase
0 69 (88%) 21 (81%) 106 (95%)
1–2 9 (12%) 5 (19%) 6 (5%)
Weight changes
0 64 (82%) 23 (88%) 99 (88%)
1–2 12 (15%) 3 (12%) 13 (12%)
3 2 (3%) 0 0
Sweating
0 51 (65%) 21 (81%) 104 (93%)
1–2 26 (33%) 5 (19%) 8 (7%)
3 1 (1%) 0 0
Oedema
0 71 (91%) 22 (85%) 102 (91%)
1–2 7 (9%) 4 (15%) 10 (9%)
Blood-pressure 
changes
0 72 (92%) 26 (100%) 109 (97%)
1–2 5 (6%) 0 3 (3%)
3 1 (1%) 0 0
(Continues in next column)
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Of the 18 events among men assigned oestrogen 
patches, nine (50%) occurred more than 30 days (and in 
four cases more than 12 months) after oestrogen was 
stopped and LHRHa was started. 13 (72%) of the 
18 events in the oestrogen-patch group and four (67%) 
of the six in the LHRHa group were deemed possibly 
related to the allocated trial treatment by one or both 
independent reviewers. These outcome events included 
six in the oestrogen-patch group that occurred more 
than 30 days after the patients had switched to LHRHa. 
In the oestrogen-patch group, 13 of the 18 cardiovascular 
events occurred in 12 men who were receiving 
regimen two.
Six (25%) of the 24 cardiovascular events were fatal, 
of which three were thought to be possibly related to 
the study treatment by the independent reviewers: 
a thromboembolic stroke in a man assigned to oestrogen 
patches and using them at the time of the event 
(36 months); a myocardial infarction in a man assigned 
to LHRHa and receiving it at the time of the event 
(2 months); and a pulmonary embolism in a man 
assigned to oestrogen patches who had switched to 
LHRHa 16 months before death. One further death 
potentially related to treatment was reported up to July, 
2011—an acute myocardial infarction in a patient who 
was assigned to LHRHa and had continued to take that 
treatment until death (33 months).
31 events were deemed not to meet the primary-
outcome deﬁ nitions: non-cardiac chest pain or investi-
gation for a silent myocardial infarction that was not 
conﬁ rmed (n=6); symptoms that might indicate con-
gestive cardiac failure or venous thromboembolism, 
such as dyspnoea or leg swelling, but for which the 
causes were not conﬁ rmed (n=5); other cardiac events, 
including atrial ﬁ brillation, hypotension, hypertension, 
and non-embolic peripheral vascular disease (n=11); 
other medical events (n=4); and symptoms associated 
with an outcome event that did not constitute a separate 
event (n=5).
In men who were still receiving the allocated treatment 
without additional therapy at 6 months, mean fasting 
glucose had increased in the LHRHa group and de-
creased in the oestrogen-patches group, which led to a 
signiﬁ cant diﬀ erence between groups (table 3, ﬁ gure 2). 
In men who remained on assigned treatments at 
12 months, fasting glucose concentrations increased 
further in the LHRHa arm but remained similar in the 
oestrogen-patches group, with the mean changes from 
baseline being 0·33 mmol/L (5·5%) and –0·16 mmol/L 
(–2·4%), respectively (p=0·004).
Mean fasting cholesterol concentration increased in 
the LHRHa group at 6 months, compared with a small 
decrease in recipients of oestrogen patches (table 3, 
ﬁ gure 2). At 12 months, the mean value was similar to 
that at 6 months in the LHRHa group (5·31 mmol/L), 
but had decreased further in the oestrogen-patches group 
(4·56 mmol/L). Mean changes from baseline 
were 0·20 mmol/L (4·1%) in the LHRHa group and 
–0·23 mmol/L (–3·3%) in the oestrogen-patches group 
(p<0·0001). By contrast, HDL cholesterol concentrations 
had in creased to a similar degree in the two groups at 
6 months and 12 months (table 3).
Mean weight had increased by similar amounts in 
the two treatment groups at 6 months (table 3) and 
12 months. Diastolic blood pressure had increased in the 
LHRHa group at 6 months and decreased in the 
oestrogen-patches group, but changes were small, as 
were changes in systolic blood pressure (table 3). These 
data were supported by those for adverse eﬀ ects, with 
only a few reports being made of substantial changes in 
weight or blood pressure (table 4). Data on blood pressure 
were not collected at 12 months. Values for cardiovascular 
risk factors were similar after exclusion of patients 
randomised to regimen one of the oestrogen patches.
Other adverse events were largely as expected, and 
were generally mild in the two treatment groups (table 4). 
As anticipated, the most frequently reported symptoms 
at 6 months in men still receiving their allocated 
treatment were related to sexual function, and, in some 
cases were severe (table 4). Gynaecomastia was reported 
on both treatments, but was more frequently reported in 
the oestrogen-patch group than in the LHRHa group, 
and in a small number of cases was symptomatic. By 
contrast, hot ﬂ ushes were more frequently reported for 
patients in the LHRHa group than in the oestrogen-
patches group (table 4). Minor dermatological problems 
associated with use of oestrogen patches were reported 
for 58 (42%) of 138 men, compared with ten (13%) of 
78 in the LHRHa group. In the two groups all reported 
symptoms were grade 1–2 and included pruritis, erythema, 
eczema, urticaria, change in skin pigmentation 
(oestrogen-patches group only), and hair changes 
LHRHa (n=78*) OP regimen 
one (n=26)
OP regimen 
two (n=112)
(Continued from previous column)
Chest pain
0 73 (94%) 26 (100%) 110 (98%)
1–2 4 (5%) 0 1 (1%)
3 1 (1%) 0 1 (1%)
Other
0 55 (71%) 18 (69%) 89 (79%)
1–2 21 (27%) 7 (27%) 22 (20%)
3 2 (3%) 
(palpitations, 
hyperglycaemia)
1 (4%) 
(urinary 
retention)
1 (1%) 
(angioplasty)
LHRHa=luteinising-hormone-releasing-hormone agonists. OP=oestrogen 
patches. *One LHRHa patient with no 6-month toxic-eﬀ ect data available was 
excluded. †Data were missing for three patients (one LHRHa, two OP regimen two). 
‡Data were missing for four patients (two LHRHa, two OP regimen two). §Rates of 
skin toxic eﬀ ects given in the text indicate the numbers of men who reported one 
or more of these symptoms. 
Table 4: Toxic eﬀ ects reported up to 6 months in men who remained on 
assigned treatment without additional therapy 
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(LHRHa group only). Some men reported more than 
one symptom. No grade 4 or 5 adverse events had been 
reported by 6 months and, with the exception of the 
cardiovascular events noted above, no other potentially 
treatment-related deaths had been reported in this 
cohort to July, 2011.
Discussion
Our results show that parenteral oestrogen administered 
via patches can lead to castrate testosterone concen-
trations similar to those achieved with LHRHa in men 
with locally advanced and metastatic prostate cancer. 
These ﬁ ndings conﬁ rm the results of a small pilot study.21 
In our study, which excluded patients with high baseline 
risks of cardiovascular events, the rate of cardiovascular 
complications in men receiving oestrogen patches was 
similar to that in men receiving LHRHa. Additionally, it 
was lower than rates observed with oral oestrogen by the 
Veterans Admin istration Cooperative Urological 
Research Group.15,22 Our modiﬁ ed intention-to-treat 
analysis of cardiovascular events seems to have been 
conservative, because several events attributed to the 
oestrogen-patches group occurred in men who had 
received oestrogen therapy for only a short period, or 
who had stopped treatment for a long time before the 
event occurred, or both. The analysis according to 
treatment at the time of the event provides a more 
standard assessment of toxic eﬀ ects. Data on disease 
progression and survival are not yet available because 
eﬃ  cacy will be assessed in the extended trial.
An important strength of this study is the independent, 
masked review of cardiovascular events. Several large 
population-based studies have reported associations 
between treatment with LHRHa and increased incidence 
of fatal and non-fatal cardiovascular events,12,13,23,24 but other 
studies have shown no such relation.10,25 A meta-analysis 
of eight randomised trials involving 4141 patients with 
median follow-up durations of 7·6–13·2 years compared 
im mediate versus no or delayed LHRHa treatment in 
men with non-metastatic prostate cancer. Cardiovascular 
mortality of 11% was reported and did not diﬀ er between 
groups (relative risk 0·93, 95% CI 0·79–1·10).26 Data were 
extracted from trial reports and were subject to 
inconsistencies in deﬁ nitions of events and assessment 
procedures. Eﬀ ects on non-fatal events, time to car-
diovascular death, and potential diﬀ erences relating to 
pre-existing cardiovascular disease were not assessed.
Use of parenteral oestrogens to treat prostate cancer has 
been reviewed previously (panel).27 Parenteral oestrogen 
administration should avoid the venous thrombotic risk 
associated with oral administration while providing the 
arterial beneﬁ ts attributed to oestrogen.28 A series of trials 
in Scandinavia assessed use of intramuscular 
polyoestradiol. The largest ran domised 910 patients with 
metastatic prostate cancer to receive intramuscular 
polyoestradiol or combined andro gen deprivation with 
triptorelin plus ﬂ utamide or orchidectomy. Biochemical 
progression, cancer-speciﬁ c survival, cardiac mortality, 
and overall mortality did not diﬀ er between treatment 
groups.29 Men were excluded on the basis of cardiovascular 
risk only if they had had myocardial or cerebral infarction 
within the preceding month. Cardiovascular morbidity 
was higher in both groups among those who had a history 
of major cardiovascular disease than in those who did not, 
but the diﬀ erence was greater in the polyoestradiol 
group.30 We did not assess diﬀ erences by pre-existing 
cardiovascular risk, but such analysis will be possible in 
the larger cohort of the extended trial.
The other important ﬁ nding in the polyoestradiol study 
was, as predicted, a protective eﬀ ect of oestrogen on bone 
health: 18 serious skeletal events were reported in the 
group undergoing combined androgen deprivation 
versus none in the polyoestradiol group (p=0·001).29 
Osteoporosis and associated events are important and 
costly side-eﬀ ects of LHRHa.7,9 Strategies to mitigate 
LHRHa-induced bone loss include use of 
bisphosphonates, targeting of RANKL (with, for example, 
denosumab), and use of selective oestrogen-receptor 
modulators. All these ap proaches, however, are 
expensive, but would potentially be unwarranted if an 
eﬀ ective method of achieving androgen deprivation 
without associated bone loss were available. The extended 
PATCH trial will investigate the eﬀ ects of LHRHa and 
oestrogen patches on bone health by assessment of 
fractures and bone-mineral density.
Panel: Research in context
Systematic review
In a systematic review, 20 randomised controlled trials of 
parenteral oestrogen in patients with prostate cancer were 
identiﬁ ed from electronic databases, including Medline, 
Embase, and the Cochrane Central Register of Controlled 
Trials, with no restrictions on language or publication date.27 
Relevant published papers and internet resources, such as 
trial and national drug registries, were also searched. The 
review found no consistent evidence that parenteral 
oestrogen given at doses suﬃ  cient to produce castrate 
testosterone concentrations diﬀ ered from luteinising-
hormone-releasing-hormone agonists in terms of prostate-
cancer, cardiovascular, or overall mortality. Transdermal 
oestrogen patches had shown promise in terms of activity 
and toxic-eﬀ ect proﬁ les in the treatment of locally advanced 
or metastatic prostate cancer in a single-arm pilot study.21
Interpretation
Our study provides evidence that castrate testosterone 
concentrations similar to those seen in patients taking 
luteinising-hormone-releasing-hormone agonists can be 
achieved with transdermal oestrogen. Rates of cardiovascular 
toxic eﬀ ects were similar with the two treatments and were 
lower than those seen with oral oestrogen.15 The study also 
provides data on metabolic changes associated with the two 
treatments. The trial has been extended to assess eﬃ  cacy.
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Our ﬁ ndings that fasting total cholesterol, HDL 
cholesterol, and fasting glucose con centrations in serum 
increased in patients receiving LHRHa are in keeping with 
previous reports.11,31 During the ﬁ rst year of treatment with 
LHRHa, increases of total cholesterol concentrations by 
5–10% and of HDL cholesterol by 6–12% have been 
reported in several small studies.31–34 Observed increases in 
fasting glucose concentrations by 1–2% have also been 
seen in short-term (12-week) studies,35,36 and larger changes 
have been seen in one longer-term study.34 These results 
are again consistent with our ﬁ ndings (increases of 2% 
and 6% in fasting glucose concentrations at 6 and 
12 months, respectively). The metabolic abnormalities 
associated with use of LHRHa have similarities to those in 
the metabolic syndrome: increases in obesity and 
concentrations of total and LDL cholesterol and tri-
glycerides, and decreases in lean mass and insulin 
sensitivity.11 The eﬀ ects with LHRHa, however, also include 
increases in HDL cholesterol concentrations and 
subcutaneous fat, but no eﬀ ect on blood pressure is seen.37 
The changes we noted in lipid proﬁ les in the oestrogen-
patches group are in keeping with the known beneﬁ cial 
arterial eﬀ ects of oral and parenteral oestrogen therapy,28,38 
and the decrease in glucose concentrations is consistent 
with the beneﬁ cial eﬀ ects of oestradiol on pancreatic β-cell 
function.39 A limitation of our analysis, however, is that 
data on triglycerides and LDL cholesterol were not 
collected. Changes in concomitant medication that might 
aﬀ ect lipid proﬁ les were also not recorded, but, as this was 
a randomised study, it is likely that these eﬀ ects would 
have been balanced across the arms. As the trial was not 
powered to compare changes in metabolic factors, results 
should be conﬁ rmed in future trials.
Other adverse eﬀ ects with the two treatments were 
largely as expected and were generally mild. Notable 
eﬀ ects in the oestrogen-patches group were gynaeco-
mastia and minor skin disorders. Fewer episodes of hot 
ﬂ ushes were reported than in the LHRHa group. In this 
population of elderly men, the eﬀ ects of treatments can 
be diﬃ  cult to distinguish from normal signs and 
symptoms associated with increasing age. Thus, eﬀ ects 
on wider features, such as cognition and quality of life in 
particular, require more detailed investigation.
Oestrogen patches seem to be a potential alternative to 
LHRHa for men with prostate cancer. Patches oﬀ er a 
low-cost, single therapy that can be self-administered, 
and which might avoid some of the side-eﬀ ects associated 
with LHRHa. Therefore, if shown to be eﬀ ective in phase 
3 trials, oestrogen patches might appeal to patients and 
clinicians. The observations that oestrogen did not 
increase either fasting glucose or cholesterol 
concentrations compared with LHRHa are important 
and strengthen the rationale for further assessment. For 
individual patients treatment decisions will need to be 
balanced and take into account antitumour eﬀ ects, risks 
of cardiovascular events, eﬀ ects on bone health, quality 
of life, including sexual dysfunction, and possible 
See Online for appendix
negative eﬀ ects on cognition. These latter eﬀ ects are 
commonly overlooked when physicians are deciding the 
best method of achieving androgen deprivation. A large 
phase 3 study will be required to assess all these features 
of treatment fully. Overall, though, the need to prioritise 
the assessment of a potential method of androgen 
deprivation that could avoid the toxic eﬀ ects associated 
with standard therapy, and to avoid the addition of new 
and expensive agents to counteract them, is clear.
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